CSIMarket


Scopus Biopharma Inc   (SCPS)
Other Ticker:  
 


 

Scopus Biopharma Inc

SCPS's Financial Statements and Analysis



Scopus Biopharma Inc narrowed second quarter of 2023 net loss per share of $-0.07 compare to net loss per share of $-0.16 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.08 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ -0.07 $  0 Mill
$+0.09     Unch.    



Scopus Biopharma Inc 's Revenue fell by 0 % in second quarter of 2023 (Jun 30 2023) year on year, to $0 million and declined by sequentially.


Scopus Biopharma Inc is

More on SCPS's Income Statement



Scopus Biopharma Inc in the second quarter of 2023 recorded net loss of $-2.929 million, an improvement compare to net loss of $-3.320 million in II. Quarter a year ago.

Sequentially net loss advanced

More on SCPS's Growth

Scopus Biopharma Inc Inventories
In Jun 30 2023 company's net cash and cash equivalents decreased by $-1 million


Scopus Biopharma Inc does not pay out common stock dividend.

In trailing twelve-month period Scopus Biopharma Inc payed $ -0.03 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -0.26 per share from $ -0.25.

Company issued 9.37 million shares or 30.86 % in Jun 30 2023.


More on SCPS's Dividends

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 40
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Scopus Biopharma Inc does not pay out common stock dividend.

In trailing twelve-month period Scopus Biopharma Inc had negative $ -0.03 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -0.26 per share from $ -0.25.

Company issued 9.37 million shares or 30.86 % in Jun 30 2023.


More on SCPS's Balance Sheets

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 40
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Scopus Biopharma Inc Earnings

Scopus Biopharma Inc. Shows Promising Improvement in Financials, Reducing Operating Deficit in Q2 2023

Understanding the Shareholders' Perspective on SCPS Earnings Season
The recent earnings season of April to June 30, 2023, at SCPS, has left shareholders pondering over various aspects of the company's performance. While the shareholders have not assumed any major moderation at the business during this period, they have taken notice of the company's operating deficit, which stood at $-2.928858 million. However, these numbers compare favorably to the results of the second quarter of 2022, where the operating deficit was $-3.319603 million.
One of the significant signals for the course of SCPS is its ability to reduce the operating deficit. This marks a positive trend in the company's financial picture....

Scopus Biopharma Inc Faces Operating Deficit in Q1 2023 ? What's Next for the Healthcare Powerhouse?

Scopus Biopharma Inc is a major pharmaceutical preparations company operating in the healthcare industry. The company is dedicated to the discovery and development of innovative therapies for the treatment of serious medical conditions. Scopus Biopharma Inc has a strong presence in the market and is known for its expertise in the field of biotechnology.
Over the years, Scopus Biopharma Inc has gained a reputation for its commitment to research and development and has made significant contributions to the healthcare industry. The company has a robust pipeline of products that are in various stages of development, and it has also collaborated with several leading healthcare companies to bring innovative th...


Date modified: 2023-08-15T09:25:02+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com